OncoMatch/Clinical Trials/NCT06221553
Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG
Is NCT06221553 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies B7H3 specific CAR T cell with IL-7Ra signaling domain for dipg brain tumor.
Treatment: B7H3 specific CAR T cell with IL-7Ra signaling domain — A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cell with IL-7Ra signal targeting B7H3 in children with diffuse intrinsic pontine glioma (DIPG) patients after complete standard treatments.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Intrinsic Pontine Glioma
Glioblastoma
Prior therapy
Must have received: radiation therapy
Participants must have diffuse intrinsic pontine glioma at any timepoint following completion of standard radiotherapy
Lab requirements
Kidney function
Creatinine < 5x ULN
Liver function
AST (SGOT) < 5x ULN; ALT (SGPT) < 5x ULN; Total bilirubin < 3x ULN
Cardiac function
Presence of >= grade 3 cardiac dysfunction or symptomatic arrythmia requiring intervention [excluded]
Normal organ function: AST (SGOT) < 5x ULN; ALT (SGPT) < 5x ULN; Total bilirubin < 3x ULN; Creatinine < 5x ULN; SpO2 room air >=90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify